Literature DB >> 19438425

Specialty care and education associated with greater disease-specific knowledge but not satisfaction with care for chronic hepatitis C.

L A Beste1, K Straits-Troster, S Zickmund, M Larson, M Chapko, J A Dominitz.   

Abstract

BACKGROUND: Little is known about differences among hepatitis C virus (HCV) patients managed by generalists vs. specialists with respect to patient-centred outcomes, such as disease-specific knowledge, health-related quality of life (HRQoL) and satisfaction with care. AIM: To examine selected patient-centred outcomes of HCV-related care provided in primary care, specialty care or both.
METHODS: A total of 629 chronic HCV patients completed a survey including an HCV knowledge assessment and validated instruments for satisfaction and HRQoL. Multivariable linear regression was used to compare outcomes between groups.
RESULTS: Adjusted total HCV knowledge score was lower among patients who did not attend specialty care (P < 0.01). Primary care and specialty patients did not differ in adjusted general HRQoL or satisfaction. Sixty percent of specialty patients underwent formal HCV education, which was associated with 5% higher knowledge score (P = 0.01). General HRQoL and patient satisfaction did not differ between primary care and specialty groups. Disease-specific knowledge and care satisfaction were independent of mental illness, substance abuse, socio-economic variables, history of antiviral treatment, formal HCV education and duration of time between last visit and survey completion.
CONCLUSIONS: Primary care patients with chronic HCV have lower adjusted disease-specific knowledge than specialty patients, but no difference in general HRQoL or patient satisfaction.

Entities:  

Mesh:

Year:  2009        PMID: 19438425     DOI: 10.1111/j.1365-2036.2009.04036.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

1.  A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China.

Authors:  Elizabeth Wu; Xisui Chen; Zhe Guan; Claudia Cao; Huiying Rao; Bo Feng; Melvin Chan; Sherry Fu; Andy Lin; Lai Wei; Anna S Lok
Journal:  Hepatol Int       Date:  2014-07-31       Impact factor: 6.047

2.  Effect of healthcare insurance policy on the quality of life of chronic hepatitis C patients receiving interferon α-2a plus ribavirin therapy.

Authors:  Jing Liu; Chao-Shuang Lin; Wei-Qiang Gan; Yu-Bao Zheng; Zhe-Bin Wu; Zhi-Xin Zhao; Zhi-Liang Gao
Journal:  Exp Ther Med       Date:  2012-03-16       Impact factor: 2.447

3.  Hepatitis C Virus Knowledge Among Pregnant Women with Opioid Use Disorder.

Authors:  Elizabeth E Krans; Scott D Rothenberger; Penelope K Morrison; Seo Young Park; Leah C Klocke; Mary J Turocy; Susan Zickmund
Journal:  Matern Child Health J       Date:  2018-08

4.  Increasing hepatitis C knowledge among homeless adults: results of a community-based, interdisciplinary intervention.

Authors:  Darlene Tyler; Adeline Nyamathi; Judith A Stein; Deborah Koniak-Griffin; Felicia Hodge; Lillian Gelberg
Journal:  J Behav Health Serv Res       Date:  2014-01       Impact factor: 1.505

5.  Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response.

Authors:  Samali Lubega; Uchenna Agbim; Miranda Surjadi; Megan Mahoney; Mandana Khalili
Journal:  Liver Int       Date:  2013-03-20       Impact factor: 5.828

6.  Formal patient education improves patient knowledge of hepatitis C in vulnerable populations.

Authors:  Miranda Surjadi; Cara Torruellas; Claudia Ayala; Hal F Yee; Mandana Khalili
Journal:  Dig Dis Sci       Date:  2010-10-24       Impact factor: 3.199

7.  The Patient-Provider Relationship Is Associated with Hepatitis C Treatment Eligibility: A Prospective Mixed-Methods Cohort Study.

Authors:  Shari S Rogal; Robert M Arnold; Michael Chapko; Barbara V Hanusa; Ada Youk; Galen E Switzer; Mary Ann Sevick; Nichole K Bayliss; Carolyn L Zook; Alexis Chidi; David S Obrosky; Susan L Zickmund
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.